Glenmark Therapeutics Inc., USA introduced at this time the launch of its Polyethylene Glycol 3350, Powder for Resolution, an over-the-counter laxative that can compete straight with Bayer’s MiraLAX.
The shares of Glenmark Prescribed drugs Restricted had been buying and selling at ₹1,399.35 down by ₹5.05 or 0.36 per cent on the NSE at this time at 10.15 am.
The brand new product, containing 17 grams of polyethylene glycol per capful, enters a market with substantial gross sales potential. In keeping with Nielsen information cited within the announcement, the MiraLAX Powder market achieved annual gross sales of roughly $555.7 million for the 52-week interval ending February 22, 2025.
“We’re excited to announce the launch of Polyethylene Glycol 3350, Powder for Resolution, addressing the rising demand for a brand new provider on this class,” mentioned Marc Kikuchi, President & Enterprise Head, North America for Glenmark.
- Learn additionally: Markets open combined, Energy Grid leads whereas IndusInd Financial institution slumps
Glenmark Prescribed drugs is a world pharmaceutical firm with operations in over 80 international locations and 11 manufacturing services throughout 4 continents. The corporate focuses on respiratory, dermatology, and oncology therapeutics throughout branded, generic, and OTC segments.
The corporate ranks among the many prime 100 biopharmaceutical corporations based on Scrip 100 and within the prime 50 generics and biosimilar corporations based on Generics Bulletin. In 2023, Glenmark obtained approval from the Science Based mostly Goal initiative for its greenhouse fuel emission discount targets.
